about
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver diseaseTransient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver diseasePharmacological interventions for alcoholic liver disease (alcohol-related liver disease): a network meta-analysisUltrasonography for diagnosis of cirrhosis in people with alcoholic liver diseaseS-adenosyl-L-methionine for people with alcoholic liver diseaseTransient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver diseaseNovel delivery system for natural products: Nano-curcumin formulationsCurrent Management of Alcoholic Hepatitis and Future TherapiesHypoxia-inducible factors as molecular targets for liver diseasesHepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative ActivitiesBiomarker-Based Approaches for Assessing Alcohol Use DisordersThe Role of Innate Immunity in Alcoholic Liver DiseaseHepatic non-parenchymal cells: Master regulators of alcoholic liver disease?Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-AcetylcysteineManaging alcoholic liver diseasePersonalized management of cirrhosis by non-invasive tests of liver fibrosis.Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in MexicoAlcohol and the IntestineDiagnosis and Management of Alcoholic Liver DiseaseAlcoholic Liver Disease: Role of CytokinesRegulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effectEthanol-induced oxidant stress modulates hepatic autophagy and proteasome activityAlcohol and hepatocellular carcinoma: a review and a point of viewAlcoholic liver disease: pathogenesis, management, and novel targets for therapyAcute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statementModel for End-stage Liver DiseasePrevention of portal hypertension: from variceal development to clinical decompensationInsulin resistance in clinical and experimental alcoholic liver diseaseAlcoholic and non-alcoholic steatohepatitisIL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in miceIntestinal CYP2E1: A mediator of alcohol-induced gut leakinessEffect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD)Alcoholic liver disease: the gut microbiome and liver cross talkNew advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseasesHepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver diseaseAlcoholic hepatitis: a comprehensive review of pathogenesis and treatmentAlcoholic liver disease: pathogenesis and new therapeutic targets.Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsRole of farnesoid X receptor and bile acids in alcoholic liver diseaseAbsence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice
P2860
Q24185989-6FDB4FDE-F962-4C7F-AB5B-A22C957B2C85Q24186412-58C3EE77-8932-489A-BF1C-5A07F889569BQ24186882-CCAAA800-FC30-4CA7-A1B9-F674DD8D2CA2Q24187499-D74D83BA-324A-4F2A-8A9A-48B1547DED8FQ24188235-36243F1D-1FF5-4F9D-82C8-E8945F795F88Q24202965-5A7E47E7-F4B6-4E45-913C-7F7BB702E798Q26741732-5066EC7A-E23D-47E1-82F3-6AB60EF0FDE3Q26746544-F59559AF-F82F-4686-B20B-9E606AB04729Q26752304-56E8DD63-C998-4751-9337-F375FA94D1E0Q26752622-217F07EA-BAC5-4040-9B9D-6DF7C5F14067Q26772931-6F4EA199-52D6-4B5E-AA1B-21A0726EB15CQ26773226-E803AFEC-A254-43E0-AC2D-BA6D5BF37FA7Q26773296-EC923D8E-A1E9-426E-BFBC-CB4F58746A67Q26773384-F93DE289-07E7-4C00-980C-69A59E47B3C2Q26777480-C74407EB-5197-4858-9D43-9E17020E5B79Q26777483-3E75A5EF-CA01-4491-97CB-4871B1247738Q26778035-985800EE-30E1-43E6-853F-65CB606F2D36Q26778947-CC18B123-03FB-4397-8DA2-2A5AEA67C8A4Q26781876-E1D5730C-938A-4208-B111-6F0BFFD2F7B8Q26783558-F32903BD-E031-42CD-B391-360BC700100AQ26827829-6D50D807-CC1D-4C79-BCEE-70B5AA706959Q26852284-403A101D-E6FC-4E04-B9A1-90780B11DE6EQ26860623-391F38C0-843B-4395-B467-D39E6A8124EDQ26861620-7D22F153-2EE6-4F9E-BBD8-25A3A84CD559Q26864487-F53363AF-4CD5-46CB-BF67-B5849D570F76Q26864971-F6C05D54-04A2-40B0-B40B-E4FD01F46A8FQ26865665-8FEA6C47-3C87-4288-AE1F-05E1B653BBC5Q26865988-6DB9C403-BFE7-4C31-804D-AC6BE7A57D49Q27000153-000C9E90-A9E7-4020-964E-C5721C341D75Q27008536-06FE247C-EA1B-4AC0-AED4-F425302A82CBQ27014102-12EBA807-BEEE-447E-9DBF-A4CF87F747D0Q27021000-6FF0DB8F-0130-4178-986B-4B1B7B57461EQ27025627-2F7269B0-E06E-4E7C-9211-65CE056A115BQ27026399-BD54C27E-78FF-44DC-845A-76721F218AB8Q27027380-6E5F5ADD-F2AC-49DF-88B1-458DB9F6E698Q27027418-A37FE976-A24B-427F-A28D-2B94F12B240BQ27690220-50CE9D7D-A2C3-49B6-80FA-7CC59E347970Q28070280-C709A3A0-DBF2-430B-A39F-110B1298BB04Q28086898-05AE3498-98A3-4637-9962-89421738356FQ28240106-0C587338-7168-442D-87D0-8DC11414545A
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Alcoholic liver disease.
@en
type
label
Alcoholic liver disease.
@en
prefLabel
Alcoholic liver disease.
@en
P2093
P2860
P356
P1433
P1476
Alcoholic liver disease.
@en
P2093
Arthur J McCullough
Practice Guideline Committee of the American Association for the Study of Liver Diseases
Practice Parameters Committee of the American College of Gastroenterology
Robert S O'Shea
Srinivasan Dasarathy
P2860
P304
P356
10.1002/HEP.23258
P407
P577
2010-01-01T00:00:00Z